Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 12/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.39 |
| ▸ | YARS1 | P54577 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | ALPI | P09923 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL4612310 | 1.00 | SLC7A5 (0.48) | SLC7A5ITGA4ITGB1YARS1DPP4 | |
| Tyrosine SCHEMBL27683457 | 1.00 | SLC7A5 (0.48) | SLC7A5ITGA4ITGB1YARS1DPP4 | |
| Tyrosine SCHEMBL28626712 | 1.00 | SLC7A5 (0.48) | SLC7A5ITGA4ITGB1YARS1DPP4 | |
| Tyrosine SCHEMBL999871 | 0.96 | SLC7A5 (0.52) | SLC7A5ITGA4ITGB1DPP4ALPI | |
| Tyrosine SCHEMBL3100805 | 0.93 | SLC7A5 (0.56) | SLC7A5ITGA4ITGB1YARS1DPP4 | |
| Tyrosine SCHEMBL22290100 | 0.93 | SLC7A5 (0.56) | SLC7A5ITGA4ITGB1YARS1DPP4 | |
| Tyrosine SCHEMBL1675510 | 0.93 | SLC7A5 (0.56) | SLC7A5ITGA4ITGB1YARS1DPP4 | |
| Tyrosine SCHEMBL15676202 | 0.91 | SLC7A5 (0.45) | SLC7A5ITGA4ITGB1DPP4 | |
| Tyrosine SCHEMBL5576441 | 0.90 | SLC7A5 (0.52) | SLC7A5ITGA4ITGB1ALPIPKM | |
| Tyrosine SCHEMBL29176062 | 0.89 | REN (0.39) | SLC7A5ITGA4ALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1064010-A4 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | CONNECTIVE TISSUE IMAGINEERING (US) | 2004-10-06 | — | — | EP | claimed |
| EP-1064010-A1 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | Mrs, Llc (US) | 2001-01-03 | — | — | EP | claimed |
| WO-1999045941-A1 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | MRS, LLC (US) | 1999-09-16 | — | — | WO | claimed |
| US-7666842-B2 | Elastin peptide analogs and uses thereof | Connective Tissue Imagineering, LLC (US) | 2010-02-23 | — | — | US | disclosed |
| US-20050059599-A1 | Elastin peptide analogs and uses thereof | CONNECTIVE TISSUE IMAGINEERING LLC. | 2005-03-17 | — | — | US | disclosed |
| US-6777389-B1 | INHIBITING CUTANEOUS EFFECTS OF AGING | CONNECTIVE TISSUE IMAGINEERING LLC | 2004-08-17 | — | — | US | disclosed |
| US-6069129-A | COMPOSITION FOR TREATING MAMMALIAN TISSUE COMPRISING PEPTIDE(S) OF GIVEN SEQUENCES; APPLYING TO HUMAN SKIN IN A COSMETIC OR THERAPEUTIC FORMULATION RESULTING IN ENHANCED ELASTICITY OF THE SKIN | MRS, LLC (US) | 2000-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059599-A1 | Elastin peptide analogs and uses thereof | ELANE, CUTA, ENPEP | SLC7A5 2652/4885ITGA4 4146/4885ITGB1 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.